Image via STAT News
Bristol Myers Squibb: Partnership
Bristol Myers Squibb partners with China's Hengrui Pharma on a $15.2 billion deal to advance more than a dozen early-stage drugs
Source: STAT News
The leadership read
Alliances like this can broaden biotech & pharma commercial leadership bench strength.
Market context: MitchelLake's Talent Market Index sits at 114.6 (Hot), up 16.3 on the prior month; Americas hiring signal is running steady (-1.3pts).
Bristol Myers Squibb: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 6 tracked companies; 0.2% of MitchelLake's Americas signal flow.
MitchelLake in this thematic
More signals across Biotech & Pharma
Product Launch · Americas
Gilead Sciences →Gilead Sciences' lenacapavir combination pill met primary efficacy goals in final-stage trials, positioning for regulatory approval of first once-weekly HIV treatment
Product Launch · Americas
Boehringer Ingelheim →Phase 3 trial data for obesity drug survodutide shows 19% discontinuation rate due to side effects, indicating potential safety/tolerability issues that may impact market launch strategy
Geographic Expansion · Americas
Novartis AG →Novartis is expanding its U.S. manufacturing footprint by establishing a new site in Texas
Capital Raising · EMEA
Nanobiotix →NANOBIOTIX closed a global offering including exercise of underwriters' option for additional American Depositary Shares, indicating successful capital raise
Restructuring · Asia
Samsung Biologics →Samsung Biologics experiencing significant labor disputes with ongoing work-to-rule campaign following failed wage negotiations; union demanded 14% wage increase and performance-based pay equivalent to 20% of operating profit while management offered only 6.2%
Partnership · Americas
Kin →Kin (co-founded by Kwame Taylor-Hayford) has secured ongoing partnership with Intuit to produce social content series 'Life-ing' for the financial software giant, launching in 2025. This represents new business win after previous Mailchimp partnership ended.